^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kisima (ATP128)

    i
    Other names: ATP-128, ATP128, ATP 128
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    Immunostimulant, TLR agonist
    Related drugs:
    Associations

    News

    Trials
    12ms
    ATP128 Vaccine in Combination with Ezabenlimab Promotes Antigen-Specific Immune Responses in Stage IV Colorectal Cancer in KISIMA-01 Phase 1b Trial (PEGS 2023)
    No abstract available
    P1 data • Combination therapy • Metastases
    |
    ezabenlimab (BI 754091) • Kisima (ATP128)
    1year
    A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) (clinicaltrials.gov)
    P1b, N=85, Recruiting, Amal Therapeutics
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154
    over1year
    ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells. (PubMed, Cancers (Basel))
    Importantly, this internalization step is detemined essential for the activation of the IRF3 pathway. This study validates the design of the self-adjuvanting ATP128 vaccine for cancer immunotherapy.
    Journal • IO biomarker
    |
    TLR4 (Toll Like Receptor 4) • TLR2 (Toll Like Receptor 2)
    |
    Kisima (ATP128)